Skip to main content
Fig. 5 | Breast Cancer Research

Fig. 5

From: BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer

Fig. 5

Kaplan–Meier curves of overall survival according to subtype and treatment. a Overall survival for the three subtypes according to the BluePrint standard readout, b Overall survival according to pertuzumab treatment in the HER2-type determined by BluePrint standard readout, c Overall survival according to pertuzumab treatment in other subtypes determined by BluePrint standard readout, d Overall survival for the subtypes according to the BluePrint dual-subtype readout. Subtypes with n < 10 are omitted, e Overall survival according to pertuzumab treatment in the HER2-single-type determined by BluePrint dual-subtype readout, f Overall survival according to pertuzumab treatment in the other subtypes determined by BluePrint dual-subtype readout. Shaded areas represent 95% confidence intervals. All p-values are from log-rank tests

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us